Cost‐effectiveness analysis of Dexcom ONE + real‐time continuous glucose monitoring versus self‐monitoring of blood glucose in people with type 2 diabetes in Aotearoa New Zealand

Key Points

• This analysis aims to evaluate the cost-effectiveness of real-time continuous glucose monitoring (rt-CGM) compared to self-monitoring of blood glucose (SMBG) in type 2 diabetes patients.
• Cost-effectiveness analysis from payer perspective
• Comparison between rt-CGM and SMBG
• Assessment of complications and associated costs
• RT-CGM shows a reduction in complications associated with type 2 diabetes
• Cost reductions are linked to decreased risks of complications
• Demonstrates potential for improved healthcare cost efficiency